Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ADHD
ADHD
Ironshore Pharmaceuticals Closes on $143 Million of Financing to Launch ADHD Drug
CP WIre
Thu, 08/23/18 - 09:53 am
Ironshore Pharmaceuticals
Jornay PM
ADHD
Ironshore Pharmaceuticals Closes on $143 Million of Financing to Launch ADHD Drug
Thu, 08/23/18 - 09:47 am
Ironshore Pharmaceuticals
Jornay PM
ADHD
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Yahoo/Zacks.com
Mon, 08/13/18 - 05:52 pm
Shire
Shionogi
ADHD
Japan
Intuniv
KemPharm shoots for ADHD filling in 2019
Biopharma Dive
Mon, 07/9/18 - 07:02 pm
KemPharm
ADHD
KP415
clinical trials
What is a digital medicine, exactly? Akili co-founder Adam Gazzaley explains
Medical Marketing and Media
Thu, 03/15/18 - 09:52 am
digital medicine
Akili Interactive
video games
ADHD
Shire creates separate neurosciences division for future investments; Agenus gains $28M in royalty deal
Endpoints
Mon, 01/8/18 - 11:26 am
Shire
ADHD
Neurosciences
ADHD Meds During Pregnancy Appear To Have Low Risk Of Birth Defects
Forbes
Wed, 12/13/17 - 06:31 pm
ADHD
pregnancy
birth defects
Shire announces availability of MYDAYIS(TM) for ADHD treatment in the U.S.
Seeking Alpha
Mon, 08/28/17 - 10:00 am
Shire
Mydayis
ADHD
Shire hints at ADHD spinoff, but could someone step in and buy the neuro franchise?
Fierce Pharma
Thu, 08/3/17 - 06:39 pm
Shire
ADHD
spinoffs
Shire plots an ADHD public spinoff as CEO Ornskov completes a top-to-bottom overhaul
Endpoints
Thu, 08/3/17 - 11:01 am
Shire
ADHD
Flemming Ornskov
spinoffs
Mydayis
Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta
TheStreet.com
Mon, 07/17/17 - 10:06 am
biotech
Impax Labs
FDA
generics
Concerta
ADHD
A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug
Endpoints
Wed, 06/21/17 - 09:50 am
Shire
FDA
ADHD
Mydayis
SHP465
Neos Therapeutics’ Controlled-Release ADHD Drug Get FDA Approval
Xconomy
Tue, 06/20/17 - 08:57 am
Neos Therapeutics
ADHD
FDA
Cotempla XR-ODT
Lilly's Strattera faces first wave of generic competition
BioPharma Dive
Fri, 06/2/17 - 11:31 am
Eli Lilly
Strattera
generics
ADHD
Apotex
Aurobindo
Glenmark
Teva Pharmaceutical
Another old, cheap generic is being prepped for an FDA application — made over into a ‘new’ drug for ADHD and narcolepsy
Endpoints
Wed, 05/31/17 - 09:25 am
generics
FDA
NLS Pharma
ADHD
narcolepsy
Mazindol
Two Red Hot Biotechs With Big Near-term Catalysts Ahead
Motley Fool
Mon, 05/29/17 - 12:09 pm
biotech
Portola Pharmaceuticals
betrixiban
andexanet alfa
Neos
Adzenys XR-ODT
ADHD
Cotempla XR-OTD
Concerta
Otsuka acquires ADHD drug in $100M deal for Neurovance
BioPharma Dive
Mon, 03/6/17 - 11:48 am
Otsuka
ADHD
Neurovance
centanafadine
M&A
How VAYA Pharma used Facebook ads for its ADHD campaign
Medical Marketing and Media
Tue, 02/21/17 - 10:35 pm
VAYA Pharma
Facebook
drug ads
ADHD
DTC advertising
Vayarin
Highland who? Biotech gets a $200M war chest to crack the US ADHD market
Endpoints
Mon, 01/30/17 - 10:15 am
Highland Therapeutics
ADHD
Benjorna
Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug
Endpoints
Thu, 01/19/17 - 11:49 am
Shire
FDA
ADHD
SHP465
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »